Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

PALO ALTO, Calif., May 15, 2017 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 LIBERTY study.  The LIBERTY study is designed to evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH).  Ubenimex is a well-characterized, oral, small-molecule inhibitor of leukotriene A4 hydrolase, which blocks the production of leukotriene B4 (LTB4), an inflammatory mediator implicated in PAH disease.  A total of 61 patients were enrolled across 45 sites in the U.S. and Canada in less than one year.